Programme - Life Science 2.0

Monday, 28 November

8:00-8:55
Registration 

9:00-9:05
Welcome and Introduction
Nina Rawal, Moderator, Partner and Co-Head, Trill Impact Ventures. 

9:05-9:15
Life Science 2.0
Ole Petter Ottersen, President of Karolinska Institutet.

9:15-9:35
Keynote 1: Building back better: Perspectives of big pharma - The development of COVID-19 vaccines and oral treatment: Experiences from the pandemic
Mikael Dolsten, Chief Scientific Officer Pfizer.

9:35-9:55
Keynote 2: Building back better: Perspectives from basic and translational research - How decades of basic research paved the way for new vaccines
Uğur Şahin, CEO BioNTech.

9:55-10:15.
Keynote 3: Building back better: The global perspective - Addressing global inequities and production gaps for vaccines and medicines
Noella Bigirimana, Deputy Director General, Rwanda Biomedical Centre (RBC), Rwanda.

10:15-10:55

Panel 1: Life science after COVID-19: Preserving an effective modus operandi while joining forces for universal preparedness and sustainability

• Uğur Şahin, CEO Biontech.
• Mikael Dolsten, CSO Pfizer.
• Noella Bigirimana, Deputy Director General at the Rwanda Biomedical Centre (RBC), Rwanda.
• Anders Nordström, Ambassador for Global Health, Swedish Ministry of Foreign Affairs.
• Juan Pablo Uribe, Global Director Health, Nutrition & Population and the Global Financing, World Bank.
• Anna Mia Ekström, Professor, Dept of Global Public Health, Karolinska Institutet.
• Jerome Kim, MD and Director General, International Vaccine Institute, IVI.

10:55-11:15
Coffee break

11:15-11:40
Keynote 4: Building a sustainable life science sector - Safeguarding planetary health in the context of UN's Agenda 2030.
Leif Johansson, Chairman of Astra Zeneca, introduced by Professor Annika Östman Wernerson, Karolinska Institutet.

11:40-12:20
Panel 2: Precision medicine & New Generation Clinical trials - Bringing clinical trials to a new level and accelerating the development treatment and prevention of neglected diseases.

• Michael Makanga, Executive Director, EDCTP (European & Developing Countries Clinical Trials Partnerships)
• Janne Lehtiö Professor at Dept. of Oncology and Pathology at Karolinska Institutet and Scientific director of SciLifeLab
• Anna Martling, Professor of Surgery at Karolinska Institutet, Chief physician and colorectal surgeon in Tema Cancer, Karolinska University Hospital
• Peter Asplund, Chair of the ministry inquiry on clinical trials, Ministry of Enterprise and Innovation
• Stephan Mielke, Professor of Haematology and Cell Therapy, Karolinska Institutet and Director of Centre for Allogenic Stem Cell Transplantation (CAST) at Karolinska University Hospital

12:20-12:40
Panel 3: Quo vadis? – A global perspective on the future of Life Science Sweden and Stockholm Region have high ambitions for the life science sector. How should we combine the ambition to be among the best IN the world to be best FOR the world?  

• Jenni Nordborg, Head of the Office for Life Sciences, Swedish Government Offices
• Jan Larsson, President and CEO Business Sweden
• Helena Strigård, CEO NorthX Biologics
• Anders Blanck, Managing Director of LIF
• Ketil F. Widerberg, General Manager of Oslo Cancer Cluster and Board Member of KI Holding AB

12:40-13:00
Sweden´s Life Strategy - Reframing Life Science
Presentation by Ebba Busch, Minister for Energy, Business and Industry followed by a closing discussion between the minister and Ole Petter Ottersen​ President of Karolinska Institutet

13:00-14:00
Networking Luncheon